Nordion, Manufacturer of TheraSphere®, to Host Educational Symposium at the 2013 Gastrointestinal Cancers Symposium Agenda includes new HCC clinical data and an update on TheraSphere® Phase III ...

Boston Scientific Corporation BSX recently announced favorable study outcome of the TARGET study of its TheraSphere Y-90 Glass Microspheres (TheraSphere) therapy during a late-breaking clinical trial ...

OTTAWA, Ontario--(BUSINESS WIRE)-- Nordion Inc. (TSX: NDN) (NYS: NDZ) , a leading provider of products and services for the prevention, diagnosis and treatment of disease, announced today that it has ...

OTTAWA, Ontario--(BUSINESS WIRE)-- Nordion Inc. (TSX: NDN) (NYS: NDZ) , a leading provider of products and services for the prevention, diagnosis and treatment of disease, today announced that for the ...

Nordion Inc., a leading provider of products and services for the prevention, diagnosis and treatment of disease, has announced an additional randomized, multi-centre phase III clinical trial for ...

Boston Scientific Corporation announced the EPOCH clinical trial of the TheraSphere Y-90 Glass Microspheres (TheraSphere treatment) successfully met both primary endpoints, including progression-free ...

Boston Scientific Corporation BSX recently announced receipt of the FDA’s approval for its TheraSphere Y-90 Glass Microspheres, which have been developed for the treatment of hepatocellular carcinoma ...

Boston Scientific Corporation BSX recently announced favorable study outcome of the TARGET study of its TheraSphere Y-90 Glass Microspheres (TheraSphere) therapy during a late-breaking clinical trial ...

Nordion Launches a New and Improved TheraSphere® Website to Meet the Needs of Liver Cancer Physicians, Patients and Caregivers Worldwide TheraSphere.com provides unique resources and targeted ...